Bosentan Hydrateendothelin receptor antagonist CAS# 157212-55-0 |
- MK-5172 hydrate
Catalog No.:BCC1763
CAS No.:1350462-55-3
- Telaprevir (VX-950)
Catalog No.:BCC2107
CAS No.:402957-28-2
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Danoprevir (RG7227)
Catalog No.:BCC2106
CAS No.:850876-88-9
- Narlaprevir
Catalog No.:BCC1785
CAS No.:865466-24-6
- Simeprevir
Catalog No.:BCC1949
CAS No.:923604-59-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 157212-55-0 | SDF | Download SDF |
| PubChem ID | 185462 | Appearance | Powder |
| Formula | C27H31N5O7S | M.Wt | 569.63 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (175.55 mM) Ethanol : 50 mg/mL (87.78 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide;hydrate | ||
| SMILES | CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC.O | ||
| Standard InChIKey | SXTRWVVIEPWAKM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C27H29N5O6S.H2O/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24;/h5-15,33H,16-17H2,1-4H3,(H,30,31,32);1H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Bosentan Hydrate Dilution Calculator
Bosentan Hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7555 mL | 8.7776 mL | 17.5553 mL | 35.1105 mL | 43.8881 mL |
| 5 mM | 0.3511 mL | 1.7555 mL | 3.5111 mL | 7.0221 mL | 8.7776 mL |
| 10 mM | 0.1756 mL | 0.8778 mL | 1.7555 mL | 3.5111 mL | 4.3888 mL |
| 50 mM | 0.0351 mL | 0.1756 mL | 0.3511 mL | 0.7022 mL | 0.8778 mL |
| 100 mM | 0.0176 mL | 0.0878 mL | 0.1756 mL | 0.3511 mL | 0.4389 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: Inhibiting endothelin receptor A and B with an IC50 of 15.1 ± 1.6 μM in P388/dx cells.
A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a relatively higher affinity to the endothelin A receptor than endothelin B receptor. By competitively binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle, Bosentan offset the effect of endothelin which is an extremely potent endogenous vasoconstrictor and broncho-constrictor. In addition, Bosentan decreases both pulmonary and systemic vascular resistance and is particularly applied in the treatment of pulmonary arterial hypertension. [1]
In vitro: A study was performed in vitro to measure the influence of Bosentan on the angiogenic performance of dermal microvascular endothelial cells (MVECs) and to detect the capacity of Bosentan in offsetting the antiangiogenic effects of systemic sclerosis sera. It was found that Bosentan significantly increased cell viability and offset the antiangiogenic effects of systemic sclerosis sera on dermal MVECs. [2]
In vivo: A study was conducted to investigate the effect of Bosentan on plasma leptin level after myocardial infarction in Wistar rats. After oral administration of Bosentan once daily at the dose of 100 mg/kg for 2 days, concentration of leptin in plasma significantly increased. This finding revealed that Bosentan played an crucial role on regulating leptin concentration in ischemic cardiovascular pathology. [1]
Clinical trials: A double-blind, placebo-controlled clinical trial was conducted to study the effect of bosentan on exercise capacity in a larger number of patients. 213 patients with pulmonary arterial hypertension were administered with 62.5 mg Bosentan twice daily for 4 weeks followed by either of two doses of Bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. It was found that 125 mg Bosentan was well tolerated and beneficial in patients with pulmonary arterial hypertension. [3]
References:
[1] Ostrowski RP, Januszewski SA, Kowalska ZA and Kapuscinski A. Effect of endothelin receptor antagonist bosentan on plasma leptin concentration in acute myocardial infarction in rats. Pathophysiology. 2003 Sep; 9(4): 249-56.
[2]Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, Guiducci S. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clin Exp Rheumatol. 2015 Aug; 33(4 Suppl 91): S148-52.
[3]Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM et, al. Bosentan therapy for pulmonary arterial hypertension. New Engl J Med. 2002 Mar; 346 (12): 896-903.
- 3-Amino-5-phenylpyrazole
Catalog No.:BCC8616
CAS No.:1572-10-7
- Harzianic acid
Catalog No.:BCN1838
CAS No.:157148-06-6
- Noopept
Catalog No.:BCC1804
CAS No.:157115-85-0
- Ajuforrestin A
Catalog No.:BCN8008
CAS No.:157110-18-4
- 3-Amino-4-hydroxybenzoic acid
Catalog No.:BCC8610
CAS No.:1571-72-8
- Lipedoside B-III
Catalog No.:BCC8201
CAS No.:157085-48-8
- SNAP 5089
Catalog No.:BCC7350
CAS No.:157066-77-8
- U 89843A
Catalog No.:BCC7466
CAS No.:157013-85-9
- 5,7-Dihydroxy-3,4',8-trimethoxyflavone
Catalog No.:BCN1551
CAS No.:1570-09-8
- H-D-Arg-OH
Catalog No.:BCC2868
CAS No.:157-06-2
- Wedeliatrilolactone A
Catalog No.:BCN6732
CAS No.:156993-29-2
- Grosvenorin
Catalog No.:BCN1262
CAS No.:156980-60-8
- ML-323
Catalog No.:BCC4313
CAS No.:1572414-83-5
- Travoprost
Catalog No.:BCC5189
CAS No.:157283-68-6
- DMP 777
Catalog No.:BCC1534
CAS No.:157341-41-8
- MAP4
Catalog No.:BCC6758
CAS No.:157381-42-5
- Bacoside A3
Catalog No.:BCC8128
CAS No.:157408-08-7
- Taxuspine B
Catalog No.:BCN6938
CAS No.:157414-05-6
- Coronarin D methyl ether
Catalog No.:BCN1705
CAS No.:157528-81-9
- BTS
Catalog No.:BCC5425
CAS No.:1576-37-0
- (S)-SNAP 5114
Catalog No.:BCC7117
CAS No.:157604-55-2
- Boc-Ala-OH
Catalog No.:BCC3047
CAS No.:15761-38-3
- Boc-Pro-OH
Catalog No.:BCC3435
CAS No.:15761-39-4
- NSC 632839 hydrochloride
Catalog No.:BCC2088
CAS No.:157654-67-6
Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.[Pubmed:28008226]
Drug Des Devel Ther. 2016 Dec 13;10:4017-4030.
The objectives of this study were to prepare Bosentan Hydrate (BST) microparticles as dry powder inhalations (DPIs) via spray drying and jet milling under various parameters, to comprehensively characterize the physicochemical properties of the BST hydrate microparticles, and to evaluate the aerosol dispersion performance and dissolution behavior as DPIs. The BST microparticles were successfully prepared for DPIs by spray drying from feeding solution concentrations of 1%, 3%, and 5% (w/v) and by jet milling at grinding pressures of 2, 3, and 4 MPa. The physicochemical properties of the spray-dried (SD) and jet-milled (JM) microparticles were determined via scanning electron microscopy, atomic force microscopy, dynamic light scattering particle size analysis, Karl Fischer titration, surface analysis, pycnometry, differential scanning calorimetry, powder X-ray diffraction, and Fourier transform infrared spectroscopy. The in vitro aerosol dispersion performance and drug dissolution behavior were evaluated using an Anderson cascade impactor and a Franz diffusion cell, respectively. The JM microparticles exhibited an irregular corrugated surface and a crystalline solid state, while the SD microparticles were spherical with a smooth surface and an amorphous solid state. Thus, the in vitro aerosol dispersion performance and dissolution behavior as DPIs were considerably different due to the differences in the physicochemical properties of the SD and JM microparticles. In particular, the highest grinding pressures under jet milling exhibited excellent aerosol dispersion performance with statistically higher values of 56.8%+/-2.0% of respirable fraction and 33.8%+/-2.3% of fine particle fraction and lower mass median aerodynamic diameter of 5.0+/-0.3 mum than the others (P<0.05, analysis of variance/Tukey). The drug dissolution mechanism was also affected by the physicochemical properties that determine the dissolution kinetics of the SD and JM microparticles, which were well fitted into the Higuchi and zero-order models, respectively.
